Preclinical News and Research

RSS

Interleukin-6 - new target in the battle against Ras-induced cancers

In an upcoming Genes & Development paper, Dr. Christopher Counter and colleagues at the Duke University Medical Center have identified IL6 as a new target in the battle against Ras-induced cancers.

16 Jul 2007

Natural polymer Chitin shows great healing properties

Chitin is a polymer very common in nature as part of animals' and plants' physical structures.

16 Jul 2007

Scientists develop largest ever series of human breasts cancers grafted into mice

At the Institut Curie, Inserm researchers and physicians have established the largest ever panel of human breast cancer xenografts in animal models.

13 Jul 2007

Neural stem cells for Parkinson's disease

A University of South Florida neuroscientist reports that the cutting-edge research study of human stem cells in primates with Parkinson's disease is compelling on several fronts , particularly how the transplanted cells did their job of easing disease symptoms.

11 Jul 2007

Potential role of milk thistle as an anticancer agent

Milk thistle extract, an herbal remedy since the times of the ancient Greeks and Romans, is today one of the most popular herbal supplements, with U.S. retail sales of nearly nine million dollars.

11 Jul 2007

Catalyst Pharmaceutical Partners starts U.S. phase II trial of CPP-109 in patients with cocaine dependence

Catalyst Pharmaceutical Partners, Inc. a specialty pharmaceutical company that acquires or in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, today announced that it has initiated its randomized, double-blind, placebo-controlled U.S. Phase II clinical trial of CPP-109 in patients with cocaine dependence.

11 Jul 2007

Peregrine licenses worldwide rights to a novel anti-angiogenesis technology

Peregrine Pharmaceuticals, Inc. has announced that it has licensed worldwide exclusive rights to a novel anti-angiogenesis technology from The University of Texas M. D. Anderson Cancer Center.

10 Jul 2007

Gene therapy offers promising approach to tackle pancreatic cancer

A molecularly engineered therapy selectively embeds a gene in pancreatic cancer that shrinks or eradicates tumors, inhibits metastasis, and prolongs survival with virtually no toxicity, researchers from The University of Texas M. D. Anderson Cancer Center report in the July 9 edition of Cancer Cell.

10 Jul 2007

Pieris progresses proprietary asthma program

Pieris AG, a bio-pharmaceutical company developing Anticalins, a novel class of targeted human protein therapeutics, today announced significant progress in validating novel, effective products for the potential treatment of asthma.

10 Jul 2007

Biomira files NDA for novel inhibitor of hypoxia-inducible factor-1 alpha

Biomira Inc. has announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for PX-478. PX-478 has been shown in preclinical studies to inhibit hypoxia-inducible factor (HIF)-1 alpha, a protein that controls the transcription of a number of genes whose products are important for tumor growth and survival.

4 Jul 2007

New genetic test advances detection and diagnosis of muscular dystrophy

A new genetic test targeting the most common types of muscular dystrophy--those caused by mutations in the dystrophin gene--is far quicker with greater accuracy and sensitivity than existing tests.

28 Jun 2007

Bayer and Onyx submit supplemental NDA for Nexavar

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have announced that a Supplemental New Drug Application (sNDA) for Nexavar (sorafenib) tablets has been submitted to the U.S. Food and Drug Administration (FDA) for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer. Nexavar is currently approved in more than 50 countries for the treatment of advanced kidney cancer.

28 Jun 2007

Amphinase molecule from frog could provide first drug treatment for brain tumours

A synthetic version of a molecule found in the egg cells of the Northern Leopard frog (Rana pipiens) could provide the world with the first drug treatment for brain tumours.

27 Jun 2007

Vaccine for human cytomegalovirus

Researchers at the University of California, San Diego (UCSD) Skaggs School of Pharmacy and Pharmaceutical Sciences have patented a strategy for developing a human vaccine to prevent against Human Cytomegalovirus (hCMV) infection and disease.

23 Jun 2007

Toronto at forefront of stem cell technology

A $20-million deal announced to license Canadian stem cell technology in the U.S. underscores the Toronto area's global leadership in stem cell research.

23 Jun 2007

Arpida receives FDA approval to initiate Phase II trial with intravenous iclaprim

Arpida Ltd. has announced that it has received approval from the US Food and Drug Administration for a Phase II trial with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare-associated pneumonia (HCAP) suspected or confirmed to be due to Gram-positive pathogens.

23 Jun 2007

Anacor finds novel mechanism for lead anti-fungal drug, AN2690

Anacor Pharmaceuticals, a privately held pharmaceutical company, has announced that the journal Science will publish results of research that details how AN2690, the company's lead clinical candidate, kills fungal cells by interfering with synthesis of a specific protein required for fungal growth.

23 Jun 2007

PepTcell vaccine could provide immunity against all strains of influenza virus

Previously undisclosed pre-clinical data showing how a new flu vaccine has the potential to protect against all strains of influenza, including pandemic and annual, was presented by PepTcell, at the 2007 Options for the Control of Influenza VI (Options) Conference, in Toronto, Canada.

20 Jun 2007

Reports of abnormal behaviour sends Tamiflu back to the drawing board

The manufacturers of the bird flu drug Tamiflu are about to repeat basic research and clinical trials on the high profile influenza drug.

20 Jun 2007

Newer breast cancer drug may protect heart

By uncovering how one breast cancer drug protects the heart and another does not, Duke University Medical Center researchers believe they may have opened up a new way to screen drugs for possible heart-related side effects and to develop new drugs.

16 Jun 2007